The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Non-Hodgkin’s Lymphomas (NHL) have been updated to include ofatumumab (Arzerra) and romidepsin (Istodax). Ofatumumab was added to the NCCN Guidelines as a treatment option for relapsed/refractory disease in patients with chronic lymphocytic leukemia, with and without a 17p deletion. In addition, the updated guidelines include romidepsin as a systemic treatment option for patients with mycosis fungoides and Szary syndrome.
Following the recent FDA approval of pazopanib (Votrient), NCCN updated its guidelines for renal cell carcinoma to include this agent as a first-line therapy option for those with predominant clear cell histology and for those with non–clear cell histology. Also, pazopanib has been incorporated into options for subsequent therapy in those with predominant clear cell histology after cytokine therapy and after other tyrosine kinase inhibitors.